Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New symbol for medicines in Spain

This article was originally published in Scrip

Executive Summary

Medicines with side-effects that may affect a patient's ability to drive are to carry warning symbol on their outer packaging, says the Spanish ministry of health.AEMPS (the Spanish medicines agency) is reviewing which medicines should carry the symbol, starting with analgesics, psychopharmaceuticals and antihistamines. Packaging will be emblazoned with the image of a car within a red triangle with the warning "Drivers: read patient information leaflet" written below. The initiative comes under a royal decree published last year which regulates the authorisation, registration and dispensing of medicines.

You may also be interested in...



Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Voluntary EU Joint Clinical Assessments ‘Risk Access To Medicines’

Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.

UsernamePublicRestriction

Register

SC032151

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel